

Title	In vitro quantification of sequential metabolism kinetics of $\Delta^9$ -tetrahydrocannabinol and its metabolites
Keywords (up to 5)	Metabolism, cannabinoid
Authors	Gabriela I. PATILEA-VRANA <sup>1</sup> and Jashvant D. UNADKAT <sup>1</sup>  <sup>1</sup> <i>Department of Pharmaceutics, University of Washington, USA</i>
Abstract	<p>Use of marijuana during pregnancy has been associated with negative outcomes<sup>1</sup>. The most abundant and psychoactive component in cannabis, <math>\Delta^9</math>-tetrahydrocannabinol (THC) and its active metabolite 11-OH-THC, likely perpetrate fetal risks. Determining fetal exposure to THC/11-OH-THC to assess fetal/neonatal risks from maternal consumption of marijuana is ethically and logistically challenging. An alternative is to use physiologically-based pharmacokinetic (PBPK) modeling and simulation to predict maternal cannabinoid exposure, as this is the driving force of fetal cannabinoid exposure. Here, we report metabolic kinetic parameters (<math>V_{max}</math> and <math>K_m</math>) necessary for building a linked THC/11-OH-THC maternal PBPK model. Substrate depletion studies were conducted using pooled (n=50) human liver microsomes in the presence of co-factors NADPH and UDPGA (cytochrome P450 (CYP) and UGT enzymes, respectively). Substrate depletion and metabolite formation was monitored via LC-MS/MS. Depletion and formation kinetics were analyzed and used as initial estimates for estimating <math>V_{max}</math> and <math>K_m</math> parameters using a comprehensive sequential metabolism model built in Phoenix (Certara). THC is metabolized to 11-OH-THC with <math>K_m = 0.14 \pm 0.03 \mu\text{M}</math> and <math>V_{max} = 0.76 \pm 0.17 \text{ nmol/min/mg}</math> and to other metabolites with <math>K_m = 5.24 \pm 9.39 \mu\text{M}</math> and <math>V_{max} = 2.30 \pm 2.82 \text{ ml/min/mg}</math>. Majority of THC is metabolized to 11-OH-THC via CYP2C9 while 7% of THC is depleted via CYP3A4. 11-OH-THC is metabolized to COOH-THC with <math>K_m = 0.53 \pm 0.13 \mu\text{M}</math> and <math>V_{max} = 0.0056 \pm 0.0004 \text{ nmol/min/mg}</math> and to other metabolites with <math>K_m = 19.46 \pm 26.24 \mu\text{M}</math> and <math>V_{max} = 8.92 \pm 14.24 \text{ nmol/min/mg}</math>. Formation of COOH-THC accounts for 2.3% of 11-OH-THC depletion, making COOH-THC not the major metabolite of 11-OH-THC. 11-OH-THC was depleted by UGT enzymes with <math>K_m = 0.64 \pm 0.15 \mu\text{M}</math> and <math>V_{max} = 0.36 \pm 0.10 \text{ nmol/min/mg}</math>. UGT and CYP enzymes account for 54% and 46% depletion of 11-OH-THC, respectively. The mechanistic information presented here will be incorporated into a maternal-fetal PBPK model previously developed<sup>2</sup> to predict cannabinoid maternal and fetal exposure.</p>
References	<ol style="list-style-type: none"> <li>Grant, K.S., Petroff, R., Isoherranen, N., Stella, N. &amp; Burbacher, T.M. Cannabis Use during Pregnancy: Pharmacokinetics and Effects on Child Development. <i>Pharmacol Ther</i>, (2017).</li> <li>Zhang, Z., Imperial, M.Z., Patilea-Vrana, G.I., Wedagedera, J., Gaohua, L. &amp; Unadkat, J.D. Development of a Novel Maternal-Fetal Physiologically Based Pharmacokinetic Model I: Insights into Factors that Determine Fetal Drug Exposure through Simulations and Sensitivity Analyses. <i>Drug Metab Dispos</i>, (2017).</li> </ol>